Payment overview · 2025
General Payments
$1,038.80
48 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffery Jerome Grace, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · BUFFALO, NY · NPI 1841247921
Verified facts
What the public records show
CMS Open Payments records show Jeffery Jerome Grace, M.D. received $1,038.80 in general payments during 2025 across 48 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Ingrezza, Invega Sustenna, Rexulti.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vivitrol by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Invega Sustenna by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $222.79 | 21.4% | 13 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $160.66 | 15.5% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $157.34 | 15.2% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $129.53 | 12.5% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.64 | 12.1% | 6 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $83.43 | 8.0% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $79.83 | 7.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.79 | 3.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.29 | 2.2% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $15.50 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,038.80 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $160.66 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $157.34 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $125.64 | 6 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $111.65 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $111.14 | 7 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $85.91 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $83.43 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $65.65 | 3 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $52.34 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.79 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clozapine | Clozapine | 488 | 28 |
| Bupropion Xl | Bupropion Hcl | 346 | 38 |
| Mirtazapine | Mirtazapine | 317 | 31 |
| Clonazepam | Clonazepam | 304 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 296 | 31 |
| Sertraline Hcl | Sertraline Hcl | 281 | 27 |
| Aripiprazole | Aripiprazole | 252 | 31 |
| Alprazolam | Alprazolam | 247 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 27 |
| Trazodone Hcl | Trazodone Hcl | 198 | 23 |
| Risperidone | Risperidone | 193 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 167 | 20 |
| Olanzapine | Olanzapine | 144 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 138 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | suppressed |
| Lamotrigine | Lamotrigine | 94 | 12 |
| Prazosin Hcl | Prazosin Hcl | 90 | 11 |
| Divalproex Sodium | Divalproex Sodium | 87 | suppressed |
| Lorazepam | Lorazepam | 77 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 69 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 65 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 60 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 60 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | suppressed |
| Gabapentin | Gabapentin | 52 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 51 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 51 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 49 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 48 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 48 | suppressed |
| Carbamazepine | Carbamazepine | 47 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 47 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Austedo | Deutetrabenazine | 31 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 23 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Risperidone Er | Risperidone Microspheres | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 19 | suppressed |
| Aristada | Aripiprazole Lauroxil | 18 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 18 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Vivitrol | Naltrexone Microspheres | 13 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,038.80 · 48 records | Teva Pharmaceuticals USA, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, LYBALVI, REXULTI, SPRAVATO, UZEDY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error